On May 28, The Shareholders Foundation announces that an investigation on behalf of investors in Repros Therapeutics Inc (NASDAQ:RPRX) shares was launched over potential breaches of fiduciary duties by certain officers and directors at Repros Therapeutics Inc. Repros Therapeutics Inc (NASDAQ:RPRX) weekly performance is 6.13%. On last trading day company shares ended up $16.27. Analysts mean target price for the company is $31.50. Repros Therapeutics Inc (NASDAQ:RPRX) distance from 50-day simple moving average (SMA50) is -2.28%.
Linn Energy LLC (NASDAQ:LINE)‘s stock had its “neutral” rating reaffirmed by JPMorgan Chase & Co. in a research note issued on Tuesday. They currently have a $31.00 target price on the stock, up from their previous target price of $30.00. JPMorgan Chase & Co.’s target price would suggest a potential upside of 8.70% from the stock’s previous close. Linn Energy LLC (NASDAQ:LINE) shares advanced 1.12% in last trading session and ended the day on $28.84. Gross Margin is 82.30% and its return on assets is -5.60%. Linn Energy LLC (NASDAQ:LINE) quarterly performance is -5.84%.
On May 28, Merck & Co., Inc. (NYSE:MRK), a leading international healthcare company, declared that its Board of Directors has approved a quarterly dividend for the company’s stockholders. The quarterly dividend payable is of $0.44 on every share of Merck’s ordinary stock. The dividend will be payable for the third quarter of 2014. The payment will be made to the stockholders on July 8, 2014 as per the record at the business closing on June 16, 2014. Merck & Co., Inc. (NYSE:MRK) shares moved up 2.30% in last trading session and was closed at $57.70 while trading in range of $56.60 – $57.79. Merck & Co., Inc. (NYSE:MRK) year to date (YTD) performance is 16.19%.
Abbott Laboratories (NYSE:ABT) announced that it expects its acquisition of Chile’s biggest drugmaker, CFR Pharmaceuticals SA, to close in 3Q 2014. Abbott, earlier this month, offered to acquire CFR for $2.9 billion. The acquisition move adds the string of deals that the company intends to enter as it seeks growth and bigger value for the shareholders in the markets that it does not already enjoy good performance. Abbott Laboratories (NYSE:ABT) ended the last trading day at $39.60. Company weekly volatility is calculated as 0.81% and price to cash ratio as 8.44. Abbott Laboratories (NYSE:ABT) showed a positive weekly performance of 0.10%.
On May 21, Actelion Ltd (OTCMKTS:ALIOF) has launched Opsumit as a new treatment option for patients with pulmonary arterial hypertension (PAH) in England. The drug, which received EU marketing authorisation in December 2013, is indicated for use as a monotherapy or in combination for the long-term treatment of PAH in adult patients. England is one of the first countries to make Opsumit available to prescribe. Actelion Ltd (OTCMKTS:ALIOF) net profit margin is 13.60% and weekly performance is 0.10%. On last trading day company shares ended up $98.32. Analysts mean target price for the company is $41.47. Actelion Ltd (OTCMKTS:ALIOF) distance from 50-day simple moving average (SMA50) is 2.51%.
Leave a Reply